newsfilter
← Latest News
GlobeNewswire·

Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development

NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company focused on the development and supply of nature-derived